相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
Friederike Holze et al.
NEUROPSYCHOPHARMACOLOGY (2021)
A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain
Nakul Ravi Raval et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
A non-hallucinogenic psychedelic analogue with therapeutic potential
Lindsay P. Cameron et al.
NATURE (2021)
Psychedelic-inspired drug discovery using an engineered biosensor
Chunyang Dong et al.
CELL (2021)
New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review
Fabrizio Schifano et al.
EXPERIMENTAL NEUROLOGY (2021)
Trial of Psilocybin versus Escitalopram for Depression
Robin Carhart-Harris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
Natalie Hesselgrave et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial
Alan K. Davis et al.
JAMA PSYCHIATRY (2021)
LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1
Ramona M. Rodriguiz et al.
SCIENTIFIC REPORTS (2021)
Investigation of the Structure-Activity Relationships of Psilocybin Analogues
Adam K. Klein et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
Psychedelics and Psychedelic-Assisted Psychotherapy
Collin M. Reiff et al.
AMERICAN JOURNAL OF PSYCHIATRY (2020)
Virtual discovery of melatonin receptor ligands to modulate circadian rhythms
Reed M. Stein et al.
NATURE (2020)
Psychedelic Psychiatry's Brave New World
David Nutt et al.
CELL (2020)
TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome
Reid H. J. Olsen et al.
NATURE CHEMICAL BIOLOGY (2020)
Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
Adam L. Halberstadt et al.
NEUROPHARMACOLOGY (2020)
Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
Kuglae Kim et al.
CELL (2020)
Targeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders
Ege T. Kavalali et al.
NEURON (2020)
Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of β-arrestin 2 and miniGαq bioassays
Eline Pottie et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Ultra-large library docking for discovering new chemotypes
Jiankun Lyu et al.
NATURE (2019)
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
Martin K. Madsen et al.
NEUROPSYCHOPHARMACOLOGY (2019)
Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport
Jonathan A. Coleman et al.
NATURE (2019)
Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs
Bryan L. Roth
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2019)
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
R. L. Carhart-Harris et al.
PSYCHOPHARMACOLOGY (2018)
Dark Classics in Chemical Neuroscience: Mescaline
Bruce K. Cassels et al.
ACS CHEMICAL NEUROSCIENCE (2018)
Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor
Tao Che et al.
CELL (2018)
5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology
Yao Peng et al.
CELL (2018)
Psychedelics Promote Structural and Functional Neural Plasticity
Calvin Ly et al.
CELL REPORTS (2018)
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Leor Roseman et al.
FRONTIERS IN PHARMACOLOGY (2018)
Psilocybin and Mental Health-Don't Lose Control
Joseph M. Barnby et al.
FRONTIERS IN PSYCHIATRY (2018)
Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor
Katrin H. Preller et al.
ELIFE (2018)
Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music
Frederick S. Barrett et al.
CEREBRAL CORTEX (2018)
How Ligands Illuminate GPCR Molecular Pharmacology
Daniel Wacker et al.
CELL (2017)
Crystal Structure of an LSD-Bound Human Serotonin Receptor
Daniel Wacker et al.
CELL (2017)
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Anna Rickli et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
Psilocybin for depression and anxiety associated with life-threatening illnesses
John D. McCorvy et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Analysis of protein-coding genetic variation in 60,706 humans
Monkol Lek et al.
NATURE (2016)
In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1
Linda D. Simmler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L. Carhart-Harris et al.
LANCET PSYCHIATRY (2016)
PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome
Wesley K. Kroeze et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
Hallucinogenic drugs in pre-Columbian Mesoamerican cultures
F. J. Carod-Artal
NEUROLOGIA (2015)
Receptor interaction profiles of novel N-2-methoxybenzyl (NSOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)
Anna Rickli et al.
NEUROPHARMACOLOGY (2015)
PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome
Wesley K. Kroeze et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2015)
Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT2A receptors, in mice
William E. Fantegrossi et al.
PSYCHOPHARMACOLOGY (2015)
Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2c Agonists
Martin Hansen et al.
ACS CHEMICAL NEUROSCIENCE (2014)
Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36
Anders Ettrup et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2014)
Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on α Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations
Michael Kometer et al.
JOURNAL OF NEUROSCIENCE (2013)
Structural Features for Functional Selectivity at Serotonin Receptors
Daniel Wacker et al.
SCIENCE (2013)
Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy')
Francois Montastruc et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model
Clint E. Canal et al.
DRUG TESTING AND ANALYSIS (2012)
Signaling pathways underlying the rapid antidepressant actions of ketamine
Ronald S. Duman et al.
NEUROPHARMACOLOGY (2012)
Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum
Matthew W. Johnson et al.
DRUG AND ALCOHOL DEPENDENCE (2011)
A Prehistoric Mural in Spain Depicting Neurotropic Psilocybe Mushrooms?
Brian P. Akers et al.
ECONOMIC BOTANY (2011)
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
Erich Studerus et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo
J. A. Allen et al.
TRANSLATIONAL PSYCHIATRY (2011)
Serotonin, But Not N-Methyltryptamines, Activates the Serotonin 2A Receptor Via a β-Arrestin2/Src/Akt Signaling Complex In Vivo
Cullen L. Schmid et al.
JOURNAL OF NEUROSCIENCE (2010)
Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management.
Steven R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PSD-95 Is Essential for Hallucinogen and Atypical Antipsychotic Drug Actions at Serotonin Receptors
Atheir I. Abbas et al.
JOURNAL OF NEUROSCIENCE (2009)
Predicting new molecular targets for known drugs
Michael J. Keiser et al.
NATURE (2009)
The 5-HT3 receptor - the relationship between structure and function
Nicholas M. Barnes et al.
NEUROPHARMACOLOGY (2009)
Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling
Kelly A. Jones et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Lorcaserin, a novel selective human 5-Hydroxytryptamine2C agonist:: In vitro and in vivo pharmacological characterization
William J. Thomsen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Opportunities and challenges of psychiatric drug discovery: Roles for scientists in academic, industry, and government settings
P. Jeffrey Conn et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo
Cullen L. Schmid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease
Steven Droogmans et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior
Javier Gonzalez-Maeso et al.
NEURON (2007)
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
Renzo Zanettini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies
MA Davies et al.
PHARMACOGENOMICS JOURNAL (2006)
The serotonin syndrome
EW Boyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Structure and Function of the Third Intracellular Loop of the 5-Hydroxytryptamine2A Receptor: The Third Intracellular Loop Is α-Helical and Binds Purified Arrestins
Edward I. Gelber et al.
JOURNAL OF NEUROCHEMISTRY (2003)
3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro
V Setola et al.
MOLECULAR PHARMACOLOGY (2003)
The interaction of a constitutively active arrestin with the arrestin-insensitive 5-HT2A receptor induces agonist-independent internalization
JA Gray et al.
MOLECULAR PHARMACOLOGY (2003)
Finding the intracellular signaling pathways affected by mood disorder treatments
JT Coyle et al.
NEURON (2003)
Salvinorin A:: A potent naturally occurring nonnitrogenous κ opioid selective agonist
BL Roth et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor
JR Bunzow et al.
MOLECULAR PHARMACOLOGY (2001)
RNA editing of the human serotonin 5-MT2C receptor:: Alterations in suicide and implications for serotonergic pharmacotherapy
CM Niswender et al.
NEUROPSYCHOPHARMACOLOGY (2001)
分享论文
